TORONTO, May 6, 2021 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN) (OTCQX:
KHRNF)(Frankfurt: A2JMZC), a
vertically integrated cannabis leader with core operations in
Latin America and Europe, is pleased to announce that Chairman
Chris Naprawa will present live at
Canaccord Genuity's 2021 Virtual Cannabis Conference on
Tuesday, May 11, 2021 at 1:00 p.m. EDT (10:00 a.m.
Khiron to Present at Canaccord Genuity's Virtual Cannabis
DATE: May 11, 2021
TIME: 1:00 p.m. EDT /
10:00 a.m. PDT
PRESENTERS: Chris Naprawa,
Chairman of Khiron Board of Directors
Recently Announced Khiron Highlights
- With the start of medical cannabis insurance coverage in
Colombia in December 2020, the Company filled approximately
135% more prescriptions in Q1 2021 than in all of 2020.
Additionally, in Q1 2021, 60% of medical cannabis prescriptions
filled in Colombia were fully
covered by insurance.
- The Company continues to benefit from favourable market
conditions and vertically integrated operations, generating gross
margins of 92% on its Medical Cannabis Product segment in Q4 2020
and filling more than 17,000 prescriptions between April 2020 and March
- Khiron recently entered into a strategic partnership with
Cellen Therapeutics, a leader in digital healthcare in the UK, to
increase patient access via medical cannabis education.
Additionally, the Company continues to expand its product offering
in the UK.
- The Company successfully delivered its first shipment of Khiron
branded EU-GMP certified medical cannabis product to Germany, providing immediate access to the
German market through its distribution partner, Nimbus Health
About Khiron Life Sciences Corp.
Khiron is a
vertically integrated medical and CPG cannabis company with core
operations in Latin America, and
operational activity in Europe and
North America. Khiron is the
leading medical cannabis provider in Colombia and the first company licensed in
Colombia for the cultivation,
production, domestic distribution and sales, and international
export of both low and high THC medical cannabis products. The
Company has filled medical cannabis prescriptions in Colombia, Peru, Germany
and the United Kingdom, and is
positioned to commence sales in Mexico and Brazil in 2021.
Leveraging wholly-owned medical clinics and proprietary
telemedicine platforms, Khiron combines a patient-oriented
approach, physician education programs, scientific expertise,
product innovation, and agricultural infrastructure to drive
prescriptions and brand loyalty. Its Wellbeing Products unit
launched the first branded CBD skincare brand in Colombia, with Kuida™ now marketed in multiple
jurisdictions in Latin America,
the US and United Kingdom. The
Company is led by Co-founder and Chief Executive Officer,
Alvaro Torres, together with an
experienced and diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information, including without limitation, statements relating to
the Company's anticipated sales and operations in Brazil and Mexico, the opening of additional satellite
clinics and locations in Colombia,
the effects of the Company's first shipment of medical cannabis
live plant material to Europe from
Colombia, the ability of
specialists to prescribe smaller quantities of medical cannabis
flower products, the Company's growth expectations and strategic
plans. Khiron undertakes no obligation to comment on analyses,
expectations or statements made by third-parties in respect of
Khiron, its securities, or financial or operating results (as
Although Khiron believes that the expectations reflected in
forward-looking statements in this press release are reasonable,
such forward-looking statements have been based on expectations,
factors and assumptions concerning future events which may prove to
be inaccurate, including without limitation those regarding the
continuance of favourable market conditions in the Company's
current markets and the anticipated demand for medical cannabis in
the markets in which the Company operates or is contemplating
Readers are cautioned that the above lists of forward-looking
statements and assumptions are not exhaustive. Since
forward-looking statements address future events and conditions, by
their very nature they involve inherent risks and uncertainties.
Actual results may differ materially from those currently
anticipated or implied by such forward-looking statements due to a
number of factors and risks. These include the risk factors
discussed in Khiron's most recently filed annual information form,
which is available on Khiron's SEDAR profile at www.sedar.com. The
forward-looking information contained in this press release is
expressly qualified by this cautionary statement and is made as of
the date hereof.
Khiron disclaims any intention and has no obligation or
responsibility, except as required by law, to update or revise any
forward-looking information, whether as a result of new
information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
T: +1 (647) 275-8984
Vice President, Communications
View original content to download
SOURCE Khiron Life Sciences Corp.